ERAS
Erasca, Inc.
There isn't enough reported data to score ERAS yet.
ERAS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ERAS's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
ERAS PE Valuation
ERAS has no meaningful PE right now: it lost money over the past year.
ERAS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect ERAS's losses to grow, with revenue holding steady.
ERAS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.99 | -$0.59 |
| Q2 2026 | -$0.95 | -$0.55 |
| Q1 2026 | -$0.93 | -$0.36 |
| Q4 2025 | -$0.44 | +$0.25 |
| Q3 2025 | -$0.40 | +$0.43 |
| Q2 2025 | -$0.40 | +$0.52 |
| Q1 2025 | -$0.57 | +$0.27 |
| Q4 2024 | -$0.69 | +$0.14 |
ERAS lost $0.99 per share over the past year, and its loss has widened in each of the last four quarters.
ERAS Quarterly Revenue
ERAS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$32.8M | -$11.2M |
| Q2 2026 | -$27.3M | -$6.7M |
| Q1 2026 | -$27.4M | +$4.2M |
| Q4 2025 | -$21.7M | +$2.8M |
| Q3 2025 | -$21.7M | +$760K |
| Q2 2025 | -$20.6M | +$8.6M |
| Q1 2025 | -$31.6M | +$1.7M |
| Q4 2024 | -$24.6M | +$306K |
ERAS has burned cash in almost every quarter: −$109M over the past year, against −$98M the year before.
ERAS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +32.9M shares |
| 1 year | +21% | +60.6M shares |
| 3 years | +129% | +194M shares |
| 5 years | +1362% | +321M shares |
| Available history | +189% | +225M shares |
ERAS has 344M diluted shares, up 21% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ERAS Net Leverage
ERAS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ERAS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.2 | Neutral |
| Stochastic | 23.9 | Neutral |
ERAS's weekly RSI is 53 (neutral) and its Stochastic is 24 (neutral).
ERAS PE vs Healthcare Sector
ERAS has no meaningful PE right now: it lost money over the past year.
ERAS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.7 | 7.6% above |
| 20 week MA | $16.5 | 4.4% below |
| 50 week MA | $13.6 | 16% above |
| 100 week MA | $7.68 | 105% above |
| 200 week MA | $5.13 | 208% above |
ERAS's trend is mixed: it's above four of its five weekly moving averages, and 208% above its 200-week average.
ERAS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $17.4 | $14.5 | -17% |
| 2022 | $14.5 | $4.10 | -72% |
| 2023 | $4.10 | $2.13 | -48% |
| 2024 | $2.13 | $2.54 | +19% |
| 2025 | $2.54 | $3.48 | +37% |
| 2026 YTD | $3.48 | $15.8 | +353% |
ERAS is up 353% so far in 2026, after finishing lower in three of the previous five years.